Moderna and Merck’s positive Phase 3 INTerpath-001 results for their personalized mRNA neoantigen therapy intismeran autogene (mRNA-4157/V940) in resected high-risk melanoma, showing a 42% reduction in recurrence or death risk versus Keytruda alone at median 24.6 months follow-up, represent the main driver of trader sentiment. These data, released in detail around the October 2026 ESMO meeting after an August interim success, align with earlier Phase 2 durability signals and have prompted the companies to state they are engaging regulators while targeting a U.S. BLA submission and 2027 launch. Competitive positioning benefits from the individualized mRNA approach’s first-in-class late-stage validation, though personalized manufacturing scale-up and combination requirements with pembrolizumab remain key variables. No filing has been announced yet, leaving room for timing shifts ahead of the June 2027 market horizon.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено1H6H1D7D30DALL
View resolved

Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання